NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM434637 Query DataSets for GSM434637
Status Public on Jul 18, 2011
Title 24h EGF versus Control replicate 3 (Agilent)
Sample type RNA
 
Channel 1
Source name Cervical cancer cell line (HeLa)
Organism Homo sapiens
Characteristics treatment: serum deprived for 24 hours, followed by exposure to EGF for 24 hours
cell line: HeLa
Treatment protocol For treatments, the cells were transferred to 60 mm dishes and cultured for 48h in complete growth medium, after which they were starved for 24h in DMEM containing 2% FBS. After serum deprivation cells were stimulated with EGF (150 ng/ml) for the indicated times.
Growth protocol HeLa cells were cultured at 37ºC in a 95/5 Air/CO2 water saturated atmosphere in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat inactivated foetal bovine serum (FBS), 2 mM L-glutamine and 100U/ml Penicilin/streptomycine (complete growth medium).
Extracted molecule total RNA
Extraction protocol Total RNA from HeLa cells was extracted using the RNeasy RNA Isolation kit (Qiagen) followed by treatment with RNase-free DNase I (Ambion, Austin, TX) following manufacturer's instructions. RNA quantification was performed with a Nanodrop spectrophotometer, and the RNA integrity was assessed using the Bioanalyzer 2100 nanoelectrophoresis Lab-on-a–chip system (Agilent, Wilmington, DE). All RNAs used had RIN (RNA integrity number) ranging between 9.3 and 10, and 28S/18S ratios between 1.67 and 2.07.
Label Cy5
Label protocol 500 ng of total RNA were reverse transcribed, amplified, labelled by in vitro transcription using the Low Input Linear Amplification Kit (Agilent 5184-3523), and hybridized following the manufacturer’s instructions (SSC wash Agilent 60-mer oligo microarray processing protocol, Version 4.1, April 2004).
 
Channel 2
Source name Cervical cancer cell line (HeLa)
Organism Homo sapiens
Characteristics treatment: serum deprived for 24 hours, followed by culture without EGF addition into the medium for 24 additional hours
cell line: HeLa
Treatment protocol For treatments, the cells were transferred to 60 mm dishes and cultured for 48h in complete growth medium, after which they were starved for 24h in DMEM containing 2% FBS. After serum deprivation cells were stimulated with EGF (150 ng/ml) for the indicated times.
Growth protocol HeLa cells were cultured at 37ºC in a 95/5 Air/CO2 water saturated atmosphere in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% heat inactivated foetal bovine serum (FBS), 2 mM L-glutamine and 100U/ml Penicilin/streptomycine (complete growth medium).
Extracted molecule total RNA
Extraction protocol Total RNA from HeLa cells was extracted using the RNeasy RNA Isolation kit (Qiagen) followed by treatment with RNase-free DNase I (Ambion, Austin, TX) following manufacturer's instructions. RNA quantification was performed with a Nanodrop spectrophotometer, and the RNA integrity was assessed using the Bioanalyzer 2100 nanoelectrophoresis Lab-on-a–chip system (Agilent, Wilmington, DE). All RNAs used had RIN (RNA integrity number) ranging between 9.3 and 10, and 28S/18S ratios between 1.67 and 2.07.
Label Cy3
Label protocol 500 ng of total RNA were reverse transcribed, amplified, labelled by in vitro transcription using the Low Input Linear Amplification Kit (Agilent 5184-3523), and hybridized following the manufacturer’s instructions (SSC wash Agilent 60-mer oligo microarray processing protocol, Version 4.1, April 2004).
 
 
Hybridization protocol Three biological replicate experiments were performed, each comparing EGF treated with untreated control HeLa cells. Each experimental pair of labelled samples was co-hybridized on two separate microarrays with dye swapping to correct for dye bias effects. Thus, six microarray hybridizations were processed for each of three biological replicates for the two time points, totalling 12 array datasets.
Scan protocol Fluorescent images were obtained using an Agilent G2565BA scanner at 100% PMT 100% laser power settings and quantified through the GenePix 6.0 software (Axon, Molecular Devices, Sunnywale, CA) using the irregular feature finding option.
Description 24h time point, biological replicate 3 of 3. Technical replicate 1 of 2. HeLa cells treated with EGF compared to untreated controls.
Data processing Extracted raw data were filtered and normalized using the Limma package developed within the Bioconductor project in the R statistical programming environment. The two channels were balanced by lowess normalization using 0.3 as the span parameter with reduced weights in control and poor quality spots, followed by scaling across chips. Differentially expressed genes for each time point were chosen using as cut off criteria a SAM FDR of 5% and an average absolute fold change (|FC|) above 1.2 .
 
Submission date Jul 29, 2009
Last update date Jul 18, 2011
Contact name Lauro Sumoy
E-mail(s) lsumoy@igtp.cat
Organization name IGTP
Department High Content Genomics and Bioinformatics
Street address Ctra. Can Ruti, Camí de les escoles s/n
City Badalona
State/province Barcelona
ZIP/Postal code 08916
Country Spain
 
Platform ID GPL4133
Series (1)
GSE17403 Multiple platform assessment of the EGF dependent transcriptome by microarray and deep tag sequencing analysis

Data table header descriptions
ID_REF
VALUE normalized log2ratio of the intensities, EGF-treated over untreated controls

Data table
ID_REF VALUE
1 -0.502112176
2 -0.221317165
3 -0.038591286
4 -0.501689166
5 -0.04025446
6 -0.14119153
7 0.070503523
8 -0.074916009
9 -0.108665265
10 0.124039684
11 -0.04025446
12 -0.061561414
13 -0.374364322
14 -0.192460972
15 0.087688028
16 -0.334933542
17 -0.094663093
18 -0.156990877
19 -0.330065334
20 -0.103302838

Total number of rows: 45220

Table truncated, full table size 798 Kbytes.




Supplementary file Size Download File type/resource
GSM434637_EG_5um_24hE_251485014562_24hE3Cy5_24hC3Cy3.gpr.gz 3.1 Mb (ftp)(http) GPR
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap